Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Metamizole (dipyrone) + tramadol is an analgesic combination consisting of the non-opioid pyrazolone derivative metamizole and the synthetic opioid tramadol. Metamizole provides analgesic, antipyretic, and antispasmodic effects, likely through the inhibition of cyclooxygenase enzymes and modulation of the endocannabinoid system and descending inhibitory pain pathways. Tramadol exerts its effect via weak agonism of the mu-opioid receptor and by inhibiting the reuptake of norepinephrine and serotonin. This specific combination was evaluated in clinical trials (such as NCT01227200) by HaEmek Medical Center as an adjunct to local anesthesia for pain management during the incision and drainage of peritonsillar abscesses (PTA). It is typically used as a co-administration of generic components rather than a proprietary fixed-dose branded product in this research context.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on metamizole + tramadol.